{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:53:04Z","timestamp":1794462784927,"version":"4.9.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1053\/j.seminhematol.2024.04.002","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T07:14:53Z","timestamp":1713338093000},"page":"100-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"61","author":[{"given":"John T.","family":"Patton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2024.04.002_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-981-15-3532-1_2","article-title":"B cell receptor signaling","volume":"1254","author":"Tanaka","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"7415","key":"10.1053\/j.seminhematol.2024.04.002_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Duhren-von Minden","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.002_bib0003","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/BLCTT.S326627","article-title":"Use of BTK inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a practical guidance","volume":"12","author":"St-Pierre","year":"2022","journal-title":"Blood Lymphat Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.002_bib0005","first-page":"185","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.002_bib0006","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.04.002_bib0007","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0009","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0010","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.002_bib0011","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.002_bib0012","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1084\/jem.179.2.425","article-title":"Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells","volume":"179","author":"Cooke","year":"1994","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood.V96.1.9","article-title":"Fates of human B-cell precursors","volume":"96","author":"LeBien","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.002_bib0014","doi-asserted-by":"crossref","first-page":"e150985","DOI":"10.1172\/JCI150985","article-title":"Positive and negative selection shape the human naive B cell repertoire","volume":"132","author":"Chen","year":"2022","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.002_bib0016","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cell.2004.05.014","article-title":"Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha\/beta heterodimer","volume":"117","author":"Kraus","year":"2004","journal-title":"Cell"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.002_bib0017","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0952-7915(02)00328-X","article-title":"Antigen-dependent B-cell development","volume":"14","author":"Cariappa","year":"2002","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0018","first-page":"55","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies","volume":"14","author":"Koehrer","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0019","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1600-065X.1993.tb00843.x","article-title":"Association of Src-family kinase Lyn with B-cell antigen receptor","volume":"132","author":"Yamamoto","year":"1993","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0021","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1097-2765(02)00739-6","article-title":"Amplification of B cell antigen receptor signaling by a Syk\/ITAM positive feedback loop","volume":"10","author":"Rolli","year":"2002","journal-title":"Mol Cell"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0022","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4049\/jimmunol.1100157","article-title":"A balance of Bruton's tyrosine kinase and SHIP activation regulates B cell receptor cluster formation by controlling actin remodeling","volume":"187","author":"Liu","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0023","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.semcdb.2007.07.009","article-title":"Lipid rafts and B cell signaling","volume":"18","author":"Gupta","year":"2007","journal-title":"Semin Cell Dev Biol"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0024","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.immunol.18.1.393","article-title":"Regulation of B lymphocyte responses to foreign and self-antigens by the CD19\/CD21 complex","volume":"18","author":"Fearon","year":"2000","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cpt.85","article-title":"Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies","volume":"97","author":"Wang","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"6-7","key":"10.1053\/j.seminhematol.2024.04.002_bib0026","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev-immunol-020711-075027","article-title":"Pathogenesis of human B cell lymphomas","volume":"30","author":"Shaffer","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.04.002_bib0028","doi-asserted-by":"crossref","first-page":"23420","DOI":"10.1074\/jbc.M202485200","article-title":"Convergence of signaling pathways on the activation of ERK in B cells","volume":"277","author":"Jacob","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0029","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1600-065X.2009.00838.x","article-title":"Phosphoinositide 3-kinase-regulated adapters in lymphocyte activation","volume":"232","author":"Zhang","year":"2009","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0030","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41598-018-19460-5","article-title":"PI3K induces B-cell development and regulates B cell identity","volume":"8","author":"Abdelrasoul","year":"2018","journal-title":"Sci Rep"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00557","article-title":"PI3K Signaling in B Cell and T Cell Biology","volume":"5","author":"Okkenhaug","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0032","first-page":"31","article-title":"Protein kinase B (PKB\/Akt), a key mediator of the PI3K signaling pathway","volume":"346","author":"Fayard","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.002_bib0033","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nri1808","article-title":"ITAM-mediated tonic signalling through pre-BCR and BCR complexes","volume":"6","author":"Monroe","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.002_bib0034","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.002_bib0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.002_bib0036","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1074-7613(00)00079-0","article-title":"BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation","volume":"13","author":"Okada","year":"2000","journal-title":"Immunity"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0037","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/ni949","article-title":"Contribution of BCAP to maintenance of mature B cells through c-Rel","volume":"4","author":"Yamazaki","year":"2003","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.002_bib0038","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/BS9.0000000000000026","article-title":"The regulators of BCR signaling during B cell activation","volume":"1","author":"Wen","year":"2019","journal-title":"Blood Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0039","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.167.1.163","article-title":"The role of the CD19\/CD21 complex in B cell processing and presentation of complement-tagged antigens","volume":"167","author":"Cherukuri","year":"2001","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0040","first-page":"123","article-title":"PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL)","volume":"393","author":"Okkenhaug","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"issue":"6597","key":"10.1053\/j.seminhematol.2024.04.002_bib0041","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/383263a0","article-title":"Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB","volume":"383","author":"Ono","year":"1996","journal-title":"Nature"},{"issue":"5489","key":"10.1053\/j.seminhematol.2024.04.002_bib0042","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.290.5489.84","article-title":"Immune inhibitory receptors","volume":"290","author":"Ravetch","year":"2000","journal-title":"Science"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0043","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0044","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3324\/haematol.2019.245795","article-title":"FcgammaRIIb-BCR coligation inhibits BCR signaling in chronic lymphocytic leukemia","volume":"106","author":"Bosch","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.002_bib0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000322375","article-title":"CD22 regulates adaptive and innate immune responses of B cells","volume":"3","author":"Kawasaki","year":"2011","journal-title":"J Innate Immun"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.002_bib0046","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/ni1072","article-title":"CD22 attenuates calcium signaling by potentiating plasma membrane calcium-ATPase activity","volume":"5","author":"Chen","year":"2004","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0047","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/mc.23228","article-title":"Nonreceptor protein tyrosine phosphatases (NRPTPs) gene family associates with the risk of hepatocellular carcinoma in a Chinese hepatitis B virus-related subjects","volume":"59","author":"Shen","year":"2020","journal-title":"Mol Carcinog"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.002_bib0048","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0167-5699(97)80025-4","article-title":"Immunoreceptor tyrosine-based inhibition motifs","volume":"18","author":"Vivier","year":"1997","journal-title":"Immunol Today"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.04.002_bib0049","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.1074\/jbc.273.21.13217","article-title":"Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk)","volume":"273","author":"Gregorieff","year":"1998","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.04.002_bib0050","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.7150\/ijbs.5141","article-title":"Regulation of the SRC family kinases by Csk","volume":"8","author":"Okada","year":"2012","journal-title":"Int J Biol Sci"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0051","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1189\/jlb.71.5.753","article-title":"The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system","volume":"71","author":"Rao","year":"2002","journal-title":"J Leukoc Biol"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.04.002_bib0052","doi-asserted-by":"crossref","first-page":"16636","DOI":"10.1074\/jbc.M112.357640","article-title":"The Syk-binding ubiquitin ligase c-Cbl mediates signaling-dependent B cell receptor ubiquitination and B cell receptor-mediated antigen processing and presentation","volume":"287","author":"Katkere","year":"2012","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.002_bib0053","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1084\/jem.191.4.641","article-title":"Cbl suppresses B cell receptor-mediated phospholipase C (PLC)-gamma2 activation by regulating B cell linker protein-PLC-gamma2 binding","volume":"191","author":"Yasuda","year":"2000","journal-title":"J Exp Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.04.002_bib0054","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"10.1053\/j.seminhematol.2024.04.002_bib0055","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.002_bib0056","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2024.04.002_bib0057","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0092-8674(02)00706-7","article-title":"Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity","volume":"109","author":"Papavasiliou","year":"2002","journal-title":"Cell"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.002_bib0058","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","article-title":"Chronic lymphocytic leukemia: revelations from the B-cell receptor","volume":"103","author":"Stevenson","year":"2004","journal-title":"Blood"},{"issue":"11-12","key":"10.1053\/j.seminhematol.2024.04.002_bib0059","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2119\/2008-00102.Catera","article-title":"Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation","volume":"14","author":"Catera","year":"2008","journal-title":"Mol Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2024.04.002_bib0060","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood-2009-09-244251","article-title":"Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin","volume":"115","author":"Chu","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0061","doi-asserted-by":"crossref","first-page":"15746","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0062","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","article-title":"ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells","volume":"109","author":"Gobessi","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.002_bib0063","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1084\/jem.20120833","article-title":"Cellular origin and pathophysiology of chronic lymphocytic leukemia","volume":"209","author":"Seifert","year":"2012","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0064","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.04.002_bib0065","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia","volume":"69","author":"Buchner","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.04.002_bib0066","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0067","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","article-title":"Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.002_bib0068","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells","volume":"23","author":"Gobessi","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"10.1053\/j.seminhematol.2024.04.002_bib0069","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1182\/bloodadvances.2020002584","article-title":"Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Emicro-TCL1 mice","volume":"4","author":"Kohlhas","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.002_bib0070","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1080\/10428190412331272703","article-title":"Microenvironmental interactions and survival of CLL B-cells","volume":"45","author":"Munk Pedersen","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.04.002_bib0071","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.002_bib0072","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0073","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","article-title":"CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia","volume":"117","author":"Sivina","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.04.002_bib0074","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0075","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"28","key":"10.1053\/j.seminhematol.2024.04.002_bib0077","doi-asserted-by":"crossref","first-page":"23769","DOI":"10.1074\/jbc.M112.372425","article-title":"Tyrosine kinase Btk is required for NK cell activation","volume":"287","author":"Bao","year":"2012","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.04.002_bib0078","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41423-019-0270-9","article-title":"T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia","volume":"17","author":"Xia","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.002_bib0079","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.002_bib0080","doi-asserted-by":"crossref","first-page":")3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8 years follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"issue":"26","key":"10.1053\/j.seminhematol.2024.04.002_bib0081","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"New Engl J Med"},{"issue":"31","key":"10.1053\/j.seminhematol.2024.04.002_bib0082","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0083","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.04.002_bib0084","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.04.002_bib0085","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0086","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.002_bib0087","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.04.002_bib0088","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab\u202f+\u202fchlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of elevate-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2024.04.002_bib0089","series-title":"17th International Conference on Malignant Lymphoma","first-page":"154","article-title":"Zanubrutinib vs bendamustine\u202f+\u202frituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study","author":"Shadman","year":"2023"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.002_bib0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"New Engl J Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.04.002_bib0091","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.002_bib0092","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"15s","key":"10.1053\/j.seminhematol.2024.04.002_bib0093","doi-asserted-by":"crossref","first-page":"e19506","DOI":"10.1200\/JCO.2021.39.15_suppl.e19506","article-title":"Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and\/or acalabrutinib","volume":"39","author":"Shadman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.002_bib0094","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.04.002_bib0095","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2024.04.002_bib0096","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily By BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.04.002_bib0097","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2024.04.002_bib0098","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1182\/blood-2023-173547","article-title":"Acquired mutations in patients with relapsed\/refractory chronic lymphocytic leukemia that progressed in the ALPINE study. American Society of Hematology Annual Meeting; San Diego, CA","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2024.04.002_bib0099","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.04.002_bib0101","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.04.002_bib0102","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2017-10-809020","article-title":"Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL","volume":"132","author":"Reiff","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0103","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.002_bib0104","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.04.002_bib0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"issue":"15","key":"10.1053\/j.seminhematol.2024.04.002_bib0106","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6682","key":"10.1053\/j.seminhematol.2024.04.002_bib0107","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0108","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","article-title":"Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity","volume":"12","author":"Lv","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0109","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2024.04.002_bib0110","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.04.002_bib0111","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.04.002_bib0112","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.04.002_bib0113","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/cancers14061571","article-title":"PI3K inhibitors for the treatment of chronic lymphocytic leukemia: current status and future perspectives","volume":"14","author":"Hus","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.002_bib0114","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.04.002_bib0115","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.04.002_bib0116","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.04.002_bib0117","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.04.002_bib0118","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.04.002_bib0119","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1021\/jm201271b","article-title":"Discovery and development of spleen tyrosine kinase (SYK) inhibitors","volume":"55","author":"Singh","year":"2012","journal-title":"J Med Chem"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.04.002_bib0120","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2024.04.002_bib0121","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.04.002_bib0122","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J Med Chem"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324000581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:37:26Z","timestamp":1718411846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324000581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0037196324000581"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.04.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}